BMJ  2006;332:1315-1319 (3 June), doi:10.1136/bmj.332.7553.1315

Clinical review

Diagnosis and management of gout

Martin Underwood, professor of general practice

Department of General Practice and Primary Care, Centre for Health Sciences, University of London, London E1 2AT. m.underwood{at}qmul.ac.uk


   Introduction
 
Gout is a common cause of acute arthritis. An ageing population, increasing obesity, and lifestyle changes will render it more common.1 Here I outline the epidemiology of gout, appraise the evidence base for its management, and suggest ways of managing idiopathic gout. Management of hyperuricaemia due to inborn errors of metabolism (for example, Lesch-Nyhan syndrome) and its prevention during cancer chemotherapy are not discussed here.


   Sources and selection criteria
 
The material for this review draws heavily on my chapter on gout in Clinical Evidence and from my work on a recent systematic review of studies on the prevention and treatment of recurrent gout. To ensure that no relevant randomised controlled trials published since the systematic review had been overlooked, I ran a previous search strategy in PubMed and the Cochrane database of systematic reviews. I identified other relevant studies from my personal database of papers on gout, did forward and backward citation tracking from other key papers, and carried out new targeted searches of multiple electronic databases.


   What is gout?
 
The clinical syndrome of gout arises from deposition of urate crystals in joints, where they cause an inflammatory response, and in soft tissues, where they do not. The classic symptom of gout affecting the big toe, podagra, literally a "foot catch," has been recognised since antiquity. Crystal deposition occurs when serum becomes saturated with urate, the final breakdown product of purine metabolism. Most patients with idiopathic gout have a genetically reduced renal excretion of urate. This alone does not usually lead to hyperuricaemia. Many other factors affect serum urate concentration (box 1).

Typically, gout produces an acute monoarthritis of rapid onset, often waking patients from sleep. The most commonly affected joints are the great toe, foot, ankle, knee, wrist, finger, and elbow, possibly because urate is more likely to crystallise in cooler parts of the body. Crystal deposits (tophi) may also develop around hands, feet, elbows, and ears. Older patients, particularly very elderly patients, can develop oligoarticular or polyarticular gout, which may be less painful and may affect osteoarthritic interphalangeal joints. Without specific treatment gout usually resolves within 7-10 days.23 After an initial acute attack patients may be free of symptoms for months or years; but some go on to have more frequent attacks and a few eventually develop chronic tophaceaous gout or permanent joint damage, or both. The characteristic radiological changes of gout are subcortical cysts without erosions. No reliable data exist on the likely recurrence rate in patients who do not have urate lowering treatment. A retrospective case series, from before the introduction of allopurinol, reported recurrence rates after a first attack of 62% after one year, 78% after two years, and 84% after three years.4


Summary points

Acute gout is common and likely to become more so

Most cases of acute gout are usually diagnosed and treated clinically

It is possible that moderate lifestyle interventions may reduce the incidence of recurrent gout

The risks and benefits of gout treatments should be carefully considered before prescribing



   Who gets gout and hyperuricaemia?
 
In most studies the prevalence of gout is at least 1%. In some countries it is substantially higher?for example, 3.6% in New Zealand Europeans and 6.4% in Maoris.5-7 Gout is much more common in men than in women; it is rare before menopause and more common in old age (fig 1).


Figure 1
 Fig 1 Prevalence of gout. Adapted from Mikuls et al5

 
Box 1 Factors affecting serum urate concentration

Factors that decrease serum urate concentration

  • Diet: low fat dairy products
  • Drugs: xanthine oxidase inhibitors (allopurinol, febuxostat), uricosuric drugs (sulfinpyrazone), uricase drugs (rasburicase), coumarin anticoagulants, and oestrogens

Factors that increase serum urate concentration

  • Diet: meat, fish, alcohol (particularly beer and spirits), obesity, and weight gain
  • Drugs: including diuretics, low dose salicylates, pyrazinamide, ethambutol, cytotoxics, and lead poisoning
  • Disease: increased purine turnover?myeloproliferative and lymphoproliferative disorders, chronic haemolytic anaemia, haemoglobinopathies, secondary polycythaemia, thalassaemia; increased purine synthesis?glucose-6-phosphate dehydrogenase deficiency, Lesch-Nyhan syndrome; reduced renal excretion?hypertension, hypothyroidism, sickle cell anaemia, hyperparathyroidism, chronic renal disease


Box 2 American College of Rheumatology preliminary criteria for the clinical diagnosis of gout14

Six or more of these criteria are needed to make a diagnosis:

  • More than one attack of acute arthritis
  • Maximum inflammation developed within one day
  • Attack of monoarthritis
  • Redness over joints
  • Painful or swollen first metatarsophalangeal joint
  • Unilateral attack on first metatarsophalangeal joint
  • Unilateral attack on tarsal joint
  • Tophus (proved or suspected)
  • Hyperuricaemia
  • Asymmetric swelling within a joint on radiograph
  • Subcortical cysts without erosions on radiograph
  • Joint fluid culture negative for organisms during attack

Gout occurs only when the serum is saturated with urate?that is, a concentration greater than 0.42 mmol/l. Coincidentally this is similar to many laboratories' normal range for men; the normal range is lower for premenopausal women. Asymptomatic hyperuricaemia is common; 9.4% of New Zealand European men have a serum urate concentration greater than 0.42 mmol/l and 2.2% have a serum urate concentration greater than 0.54 mmol/l.7 Only a minority of people with hyperuricaemia develop gout. Even when the urate concentration is 0.6 mmol/l or more, the annual incidence of gout is only 6% (fig 2).8


Figure 2
 Fig 2 Relation between serum urate concentration and annual incidence of gout. Adapted from Campion et al8

 
Lifestyle factors have an important effect on the incidence of gout. A 12 year cohort study of 47 150 gout free, male health professionals has quantified this. Incidence was higher in those who were obese or had a higher overall alcohol intake, or both (figs 3 and 4).9 10 Interestingly, beer intake, but not wine, increased the incidence of gout, probably because the purine content of beer has an effect independent of alcohol (table 1).1 9 Incidence was also greater in those with higher intakes of meat or fish. Purine rich vegetables had no effect whereas low fat dairy products were protective, possibly due to a uricosuric effect of casein and lactalbumin (table 1).11 Hyperuricaemia is associated with increased cardiovascular risk; it may be that for some high risk patients hyperuricaemia is an independent cardiovascular risk factor rather than just an association.12 It is worth while screening patients who present with gout for cardiovascular risk factors. A Dutch study found that in patients with gout who were not already known to have cardiovascular disease the prevalence of hypertension, hypercholesterolaemia, and diabetes was 39%, 8%, and 5%, respectively.13


Figure 3
 Fig 3 Effect of total alcohol intake on relative risk of first attack of gout. Adapted from Choi et al9

 
Figure 4
 Fig 4 Effect of obesity on incidence of first attack of gout. Adapted from Choi et al10

 
 
 

 

 

 
   How is gout diagnosed?
 
Identifying urate crystals in fluid from an affected joint is the definitive diagnostic test for the diagnosis of gout. In practice, this test is applied to only a minority of patients diagnosed as having gout: 11% in the health professionals study.910 Guidelines exist for clinical diagnosis without joint aspiration (box 2).14 However, patients with gout may not meet these criteria when they first present. In the acute situation it is reasonable to treat patients with suspected gout as if they had gout; inadvertent treatment for gout of patients with pseudogout or another inflammatory arthritis is unlikely to be problematic. The important differential diagnosis in the acute situation is septic arthritis. If this is suspected an immediate referral for joint aspiration is indicated.

The serum urate concentration may reduce during an acute attack; a normal urate concentration at this point does not rule out a diagnosis of gout. Table 2 summarises other suggested investigations for patients with suspected gout.

 

 


   Treatment of acute gout
 
Few robust data exist on the treatment of acute gout.16 Choice of treatment depends on the balance of risks and benefits.

Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs, specifically indometacin, are the most popular treatment for acute gout in the United Kingdom.17 Only one, low quality, placebo controlled trial has been carried out on non-steroidal anti-inflammatory drugs for gout.16 Many underpowered trials have failed to show a difference in outcome between different conventional non-steroidal anti-inflammatory drugs.16 Two large non-inferiority trials showed that clinical outcomes from indometacin and etoricoxib, a cyclo-oxygenase-2 inhibitor, were similar.16 The potential gastrointestinal and cardiovascular risks from these drugs are well documented and beyond the scope of this review. However, people who develop gout may be those at highest risk of side effects from either traditional non-steroidal anti-inflammatory drugs or cyclo-oxygenase-2 inhibitors.

 

 

Colchicine
Colchicine is the most popular treatment for acute gout in some countries, such as France.18 Although one randomised controlled trial showed that colchicine is more effective than placebo, all participants in the colchicine arm developed diarrhoea and vomiting, many before onset of pain relief.3 The high dose of colchicine, up to 6 mg, usually advised for the treatment of gout may cause unnecessary toxicity; a lower dose of 0.5 mg every eight hours may be more appropriate.19 The toxicity of intravenous colchicine is too high to justify its use.

Steroids and adrenocorticotrophic hormone
Oral, parenteral, and intra-articular steroids and adrenocorticotrophic hormone are all used to treat acute gout. No placebo controlled trials have assessed the effect of steroids or adrenocorticotrophic hormone on acute gout.16 Occasional short courses of oral steroids may be preferable to either non-steroidal anti-inflammatory drugs or colchicine, because of the lower incidence of adverse events.

Local treatments
Many cartoon images of people with gout testify to the long history of treatment by elevation and rest of the affected joint. More recently, a small controlled trial suggested benefit from the application of ice to the affected area.16

Although there is little objective evidence, clinical experience suggests that all these approaches can be effective for the treatment of acute gout. Choice should be determined by the risk of adverse events and patient preferences. For some patients with a high risk of side effects it may be appropriate to advise rest, cooling, and strong analgesics rather than any gout specific drug treatment.


   Prevention of recurrent gout
 
Few robust data exist on the prevention of recurrent gout.16 Since only a minority of people with asymptomatic hyperuricaemia ever develop gout, asymptomatic hyperuricaemia seldom requires treatment. The two exceptions are preventive treatment for some patients being treated for malignancy; and possibly for people with a high urate concentration (> 0.8 mmol/l) and high renal excretion of urate, to prevent formation of renal stones. Consequently there is no indication for routine screening for hyperuricaemia. Nevertheless, many patients receiving allopurinol do not have a recorded diagnosis of gout.20


Box 3 Suggested quality care indicators for management of gout. Adapted from Mikuls et al21

Treatment of acute gout

  • Patients presenting with acute gouty arthritis who do not have significant renal impairment (creatinine clearance ≤ 50 ml/min or creatinine concentration ≥ 167 ?mol/l) or peptic ulcer disease should be treated with one of the following:
  • A non-steroidal anti-inflammatory drug
  • Adrenocorticotrophic hormone or steroids (systemic or intra-articular)
  • Colchicine

Prevention of recurrent gout

  • Patients with gout who are obese (body mass index > 28), or who have one or more alcoholic drinks per day, should be advised to lose weight or decrease their alcohol consumption, or both
  • When starting allopurinol in patients with major renal impairment, initially use a low dose (< 300 mg/day)
  • When coprescribing a xanthine oxidase inhibitor with azothiaprine or 6-mercaptopurine, reduce dose of azothiaprine or 6-mercaptopirine by at least 50%
  • When starting a urate lowering drug in patients with gout who do not have major renal impairment (see definition above) or peptic ulcer disease, coprescribe a non-steroidal anti-inflammatory drug or colchicine to reduce the incidence of rebound gout attacks
  • Patients with asymptomatic hyperuricaemia do not need treatment
  • Uricosuric drugs should not be used in patients with significant renal impairment (see definition above) or a history of renal stones
  • Patients with gout and either tophaceous deposits, gouty erosive changes on radiographs, or more than two attacks per year should be offered urate lowering treatment
  • Patients with gout who are taking a xanthine oxidase inhibitor should have their serum urate level checked at least once during the first six months of continued use
  • Patients taking long term prophylactic oral colchicine who have major renal impairment (see definition above) should have a full blood count and creatine kinase checked at least once every six months

An increased serum urate concentration and recurrent joint pain is insufficient to diagnose gout. Careful consideration is required before starting lifelong prophylactic drug treatment with potentially serious side effects. If the patient does not seem to benefit from treatment the diagnosis should be reviewed (box 2).

For most people with occasional attacks of gout, the risks of prophylactic treatment probably outweigh the benefits. Patient preferences play an important part in the decision to prescribe prophylactic drugs; however, these drugs should be offered to patients who experience more than two acute attacks per year, have tophi, or have radiological changes.21 Urate lowering drugs shouldn't be started during an acute attack. Unless contraindicated, prophylactic colchicine or a non-steroidal anti-inflammatory drug should be prescribed for the first three months of urate lowering treatment to prevent a rebound increase in acute gout. In one trial colchicine prophylaxis reduced the incidence of rebound gout by 1.2 attacks per person over the first three months of allopurinol treatment.22


Tips for non-specialists

  • Serum urate concentrations can go down during an attack of gout
  • Oral steroids may be a safer alternative to non-steroidal anti-inflammatory drugs or colchicine for the management of acute gout
  • Urate lowering drugs are usually needed only for patients with frequent attacks of gout
  • Asymptomatic hyperuricaemia does not require treatment

The target of interventions to reduce serum urate is to decrease the serum urate concentration to below 0.36 mmol/l, well below the level at which urate crystallises.23 At this level urate should no longer crystallise and existing deposits should be mobilised. Even if this target is not reached, any reduction in urate concentration should reduce the incidence of recurrent gout.

Medication review
Some drugs, most commonly diuretics, can cause iatrogenic hyperuricaemia. The patient's regular drugs should be reviewed and consideration given to stopping any urate raising drugs.

Lifestyle changes
No controlled trials of the effect of lifestyle change on the incidence of recurrent gout have been carried out.16 Adherence to traditional low purine diets is poor and they are not usually recommended. Data from the health professionals study, however, suggest that the following relatively simple changes may have an impact on incidence of recurrent gout9-11:

  • Lose weight
  • Eat one less portion of meat or fish a day
  • Drink wine instead of beer
  • Drink a glass of skimmed milk a day.

Xanthine oxidase inhibitors
Allopurinol has been the mainstay of gout prevention since the 1960s. Its effect on incidence of recurrent gout has not been shown in placebo controlled trials.16 Nevertheless, decades of experience by doctors and patients attest to its effectiveness. However, in two trials of a new xanthine oxidase inhibitor, febuxostat, only 21% and 22% of patients taking allopurinol achieved the target urate level of less than 0.36 mmol/l.24 25 The dose of allopurinol should be titrated, if necessary up to 900 mg/day, to achieve a serum urate concentration of less than 0.36 mmol/l. Up to one fifth of patients are unable to tolerate allopurinol; some develop potentially fatal allopurinol hypersensitivity syndrome.23 Patients with renal impairment are more likely to have adverse reactions to allopurinol and should be prescribed 300 mg or less daily.21

Febuxostat may be marketed soon. Two large randomised controlled trials have shown it to be substantially more effective than allopurinol at reducing serum urate concentration to a target level of less than 0.36 mmol/l (48% and 69% v 21% and 22%).24 25 This did not, however, result in fewer acute attacks of gout when compared with the allopurinol group.24 Because febuxostat is biochemically unrelated to allopurinol it may have a role in patients who are intolerant to allopurinol.

Uricosurics
The only uricosuric routinely available in the United Kingdom is sulfinpyrazone. It works by blocking renal tubular reabsorption of urate, consequentially increasing risk of renal stones. It is unsuitable for patients with impaired renal function or a high renal excretion of urate. Evidence for its long term effect on urate concentration and recurrent gout is sparse.16

Colchicine
No controlled trials of colchicine's use as a single agent for prevention of recurrent gout have been carried out.16 However, it reduces rebound attacks for up to six months in patients starting allopurinol, indirectly supporting its use in long term prevention.22

Non-steroidal anti-inflammatory drugs
Long term treatment with non-steroidal anti-inflammatory drugs is sometimes used to prevent recurrent gout. Data from controlled trials are lacking.16

Other urate lowering drugs
Both losartan and flubiprofen may reduce serum urate concentration. Data from controlled trials on their use to prevent recurrent gout are lacking.16


   Conclusion
 
Until recently there has been little new information to inform the diagnosis and management of gout. Now there is a resurgence of interest in improving its management. In existence are new high quality epidemiological data; systematic reviews of existing evidence for treatment; evidence based quality of care indicators (box 3); new high quality controlled trials; and the first new gout specific drug to become generally available is likely to come on the market soon. Uricase drugs that break down urate are already available for specific indications; in future similar preparations may become more generally available for patients with intractable gout.

 

I thank Dawn Carnes and Lynette Edwards for their comments on earlier versions of this paper.

Competing interests: MU has received speaker fees from Pfizer, the manufacturer of valdecoxib and celecoxib and from Menarini, the manufacturer of ketoprofen and dexketoprofen. He is a current or recent applicant on research projects funded in excess of ?100 000 by the NHS health technology assessment programme, Arthritis Research Campaign, and the UK Medical Research Council.


   References
 

  1. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17: 341-5.[ISI][Medline]
  2. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987;24: 33-6.[ISI][Medline]
  3. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987;17: 301-4.[ISI][Medline]
  4. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Ann Intern Med 1961;55: 179-92.[ISI][Medline]
  5. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis 2005;64: 267-72.[Abstract/Free Full Text]
  6. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50: 2400-14.[CrossRef][ISI][Medline]
  7. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997;56: 22-6.[Abstract/Free Full Text]
  8. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987;82: 421-6.[CrossRef][Medline]
  9. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363: 1277-81.[CrossRef][ISI][Medline]
  10. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165: 742-8.[Abstract/Free Full Text]
  11. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350: 1093-103.[Abstract/Free Full Text]
  12. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118: 816-26.[CrossRef][ISI][Medline]
  13. Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 2003;20: 413-6.[Abstract/Free Full Text]
  14. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20: 895-900.[ISI][Medline]
  15. Giordano N, Santacroce C, Mattii G, Geraci S, Amendola A, Gennari C. Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol 2001;19: 661-5.[ISI][Medline]
  16. Sutaria, S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology Advance Access published April 21, 2006.doi:10.1093/rheumatology/ke1071.
  17. Gout in primary care. Drug Ther Bull 2004;42: 37-40.[Medline]
  18. Rozenberg S, Lang T, Laatar A, Koeger AC, Orcel P, Bourgerois P. Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed 1996;63: 255-61.[Medline]
  19. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003;327: 1275-6.[Free Full Text]
  20. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK general practice research database (GPRD). Rheumatology (Oxford) 2005;44: 1038-42.[CrossRef][Medline]
  21. Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50: 937-43.[CrossRef][ISI][Medline]
  22. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31: 2429-32.[ISI][Medline]
  23. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17: 319-24.[CrossRef][ISI][Medline]
  24. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353: 2450-61.[Abstract/Free Full Text]
  25. Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricaemia and gout: the 28-week APEX study. Annual scientific meeting of the American College of Rheumatology, San Diego, Nov 2005.